Stockscreener 앱 받기
3.90
0.51%
-0.02
시간 외 거래:
3.92
0.02
+0.51%
전일 마감가:
$3.92
열려 있는:
$4
하루 거래량:
58,020
Relative Volume:
0.28
시가총액:
$173.41M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-1.76%
1개월 성능:
+15.38%
6개월 성능:
-21.69%
1년 성능:
+0.00%
1일 변동 폭
$3.81
$4.05
1주일 범위
$3.56
$4.16
52주 변동 폭
$1.80
$7.20
Tuhura Biosciences Inc Stock (HURA) Company Profile
명칭
Tuhura Biosciences Inc
전화
813-875-6600
주소
10500 UNIVERSITY CENTER DR., TAMPA
HURA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
3.90 | 173.41M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-03 | 개시 | H.C. Wainwright | Buy |
| 2024-12-19 | 개시 | Rodman & Renshaw | Buy |
| 2024-11-05 | 개시 | Maxim Group | Buy |
Tuhura Biosciences Inc 주식(HURA)의 최신 뉴스
TuHURA Biosciences initiates Phase 1b/2a study of IFx-Hu2.0 in carcinoma - TipRanks
TuHURA Biosciences begins trial for metastatic cancer therapy - Investing.com
TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP) - PR Newswire
Geode Capital Management LLC Buys New Holdings in TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences Reports Cancer Immunotherapy Safe, Well Tolerated in Clinical Trial - marketscreener.com
TuHURA Biosciences and Kineta present updated results of cancer candidates - TipRanks
TuHURA And Kineta Present Updated Results From Phase I-II Study Of KVA12123 - Nasdaq
TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Resea - Longview News-Journal
Press Release Distribution & PR Platform - ACCESS Newswire
TuHURA Biosciences (NASDAQ:HURA) vs. Lakeshore Biopharma (NASDAQ:LSB) Head-To-Head Contrast - Defense World
Is TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts? - Insider Monkey
10 Best Rising Penny Stocks to Buy According to Analysts - Insider Monkey
Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study - Quantisnow
Equities Analysts Offer Predictions for HURA Q3 Earnings - Defense World
HURA: 2024 Financial Results - Zacks Small Cap Research
TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting - PR Newswire
TuHURA Biosciences hires new EVP for drug development By Investing.com - Investing.com South Africa
TuHURA Biosciences hires new EVP for drug development - Investing.com India
Tuhura Biosciences Appoints Dr. Bertrand Le Bourdonnec As Executive Vice President - MarketScreener
TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management - PR Newswire
Q2 EPS Estimate for TuHURA Biosciences Increased by Analyst - Defense World
Q3 Earnings Estimate for HURA Issued By HC Wainwright - Defense World
HC Wainwright Has Lowered Expectations for TuHURA Biosciences (NASDAQ:HURA) Stock Price - Defense World
H.C. Wainwright cuts TuHURA Biosciences target to $12; Keeps Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts TuHURA Biosciences target to $12; Keeps Buy - Investing.com
Is TuHURA Biosciences (NASDAQ:HURA) In A Good Position To Deliver On Growth Plans? - Yahoo
Charles Schwab Investment Management Inc. Purchases New Position in TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 - TradingView
TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update - PR Newswire
TuHURA Biosciences (NASDAQ:HURA) Stock Price Up 1.7% – Still a Buy? - Defense World
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
TuHURA Biosciences Announces Acquisition of Kineta, Inc. - MSN
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
TuHURA Biosciences Expands Board with New Appointment - TipRanks
TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors - Joplin Globe
TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference - Eagle-Tribune
What is HC Wainwright’s Estimate for HURA Q2 Earnings? - Defense World
KINETA, INC./DE SEC 10-K Report - TradingView
HURA stock touches 52-week low at $2 amid market fluctuations - Investing.com
Tuhura Biosciences Inc (HURA) 재무 분석
Tuhura Biosciences Inc (HURA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):